- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: GC33 | RG-7686 | RG7686 | RO-5137382 | RO5137382
Compound class: Antibody
Comment: Codrituzumab is the first-in-class, recombinant, humanized monoclonal antibody which binds to glypican-3 (GPC3). GPC3 is an oncofetal protein highly expressed in hepatocellular carcinoma (HCC) cells [1,4-5]. The anti-GPC3 antibody has been modified to carry fewer fucose sugar chains with the aim of increasing its cytotoxic activity, and therefore improving its inhibitory effect on cell growth, providing an enhanced anticancer agent.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence match identifies US7867734 as the covering patent .
|No information available.|
|Summary of Clinical Use|
|Codrituzumab is being evaluated in Phase II clinical trial as a potential treatment for metastatic hepatocellular carcinoma (HCC).|
|Mechanism Of Action and Pharmacodynamic Effects|
|Codrituzumab induces FcγRIIIa (CD16) mediated antibody-dependent cell cytotoxicity (ADCC) and/or antibody-dependent cell phagocytosis (ADCP).|